-- Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) achieved strong profitability growth in the third quarter ended 30 September 2025, with cumulative Profit Before Tax (PBT) and Profit After Tax (PAT) in the first three quarters of FY2025 both growing 43.8% respectively compared to the previous year. The achievement was spurred by cumulative revenue growth of 14.0% in the same period. For period ended Q3 FY2025, the total revenue to date stood at RM707.0 million compared to RM620.0 million in the corresponding period last year.
The growth was primarily driven by sustained demand from both the public and private sectors across all business segments, including the additional contribution from a one-off surge in insulin supply during the first half of the year following supply normalisation. The rise in the Group’s profits in the first nine months of the year compared to the corresponding period last year is mainly attributable to higher sales coupled with continued favourable price of active pharmaceutical ingredient (API) and foreign exchange costs.
Meanwhile, in Q3 FY2025, despite a marginal increase of 0.3% in revenue, compared to the preceding quarter, the Group’s PBT and PAT both rose 11.7% respectively, primarily driven by a favourable product mix as well as the continued strengthening of the Ringgit Malaysia that contributed to improved overall margins during the quarter.
Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech, commented, “As one of Malaysia’s leading pharmaceutical manufacturers, with a commitment to providing smarter solutions for a healthier life, Duopharma Biotech continues to see sustained growth opportunities, driven by the Government’s agenda. The recently tabled Budget 2026 allocating 2.7% more funding to healthcare demonstrates the Government’s commitment to strengthening the healthcare ecosystem, adding to the 13th Malaysia Plan’s continued focus on enhancing healthcare capacity, advancing pharmaceutical research and manufacturing, and promoting greater self-sufficiency within the medicine supply chain.”
Duopharma Biotech is currently actively pursuing the award of a new Ministry of Health (“MOH”) tender to supply Recombinant Human Insulin (RHI) Formulations to the MOH facilities, following the expiration of the preceding contract on 28 October 2025. Separately, the Company also holds an ongoing contract to supply 100 products to the Government’s healthcare facilities until 31 December 2026, at a combined estimated value of approximately RM684.15 million.
Leonard Ariff continued, “Regionally, Duopharma Biotech’s operations have also recorded encouraging progress through improved market penetration and growing demand in key ASEAN markets, further strengthening our international growth platform. I am heartened to see the Company’s robust position as we transition to a new leadership with the appointment of Encik Wan Amir-Jeffery Wan Abdul Majid as Group Chief Executive Officer.”
In Q3 FY2025, Duopharma Biotech paid an interim dividend of 1.5 sen per share (2024: first interim dividend of 1.0 sen per share) equivalent to RM14.43 million (2024:RM 9.62 million) in respect of financial year ending 31 December 2025. The Directors did not recommend any interim dividend for the current quarter ended 30 September 2025. (2024:Nil).
Continued recognition and excellence
Reinforcing Duopharma Biotech’s track record of excellence, the Company was recognised with the Prime Minister’s Award in the private sector category at the 2025 Integrity, Governance and Anti-Corruption Awards (AIGA). The award was presented by Prime Minister Dato’ Seri Anwar Ibrahim at the Majlis Amanat Perdana Integriti Nasional (MAPIN) which marked the launch of National Integrity Month, observed every November. Selected through a rigorous multi-stage evaluation process involving 202 public and private organisations nationwide, the award recognises the recipient organisation’s commitment to embedding integrity, good governance and anti-corruption principles into their operations.
Duopharma Biotech was also selected to showcase best practices in Malaysia’s Halal pharmaceutical production to approximately 30 delegates from the Standards and Metrology Institute for Islamic Countries (SMIIC) – an institute under the Organization of Islamic Cooperation (OIC), with a mission to establish uniformity in standardisation, metrology and accreditation activities to facilitate trade and support sustainable economic growth, consumer welfare, environment and innovation promotion for Member States.
The technical visit to the Company’s manufacturing facility in Klang – a Good Manufacturing Practices (GMP)-certified plant focusing on advanced pharmaceutical technologies, was organised by the Department of Standards Malaysia (DSM) in conjunction with the 14th SMIIC Technical Committee Week 2025 hosted in Kuala Lumpur.
Release ID: 89175978
Google
RSS